阿帕替尼对肝细胞癌治疗研究进展  

Research progress of apatinib in treatment of hepatocellular carcinoma

作　　者：赵浩然 张玉宝[1] Zhao Haoran;Zhang Yubao(Department of Hepatobiliary Surgery,Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,Heilongjiang,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院肝胆外科,黑龙江哈尔滨150081

出　　处：《肝癌电子杂志》2020年第2期48-51,共4页Electronic Journal of Liver Tumor

基　　金：北京医学奖励基金(yxjl-2020-0070-0006)。

摘　　要：多年来原发性肝癌在中国的发生率及死亡率均一直处在前五位,且复发率高,预后不良。基于国内情况,原发性肝癌发生的病理类型以肝炎相关的肝细胞癌(hepatocellular carcinoma,HCC)为主,故而HCC研究对原发性肝癌的攻坚有着至关重要的临床意义与研究价值。阿帕替尼作为国内自主研发的小分子VEGFR酪氨酸激酶抑制剂,其对HCC治疗的安全性、有效性不断在临床治疗中得以验证,具有可观的研究潜力与前景,本文就目前阿帕替尼在HCC的应用现状及研究进展进行阐述,旨在为临床应用提出有价值的参考依据。For many years,the incidence and mortality of primary liver cancer in China have been in the top five,with high recurrence rate and poor prognosis.Based on China’s national conditions,the pathological type of primary liver cancer is mainly hepatitis-related hepatocellular carcinoma(HCC).Therefore,the research for HCC can provide crucial reference on the treatment and research on primary liver cancer.Apatinib is a small molecule VEGFR tyrosine kinase inhibitor independently developed in our country.Its safety and effectiveness in HCC treatment have been continuously verified in clinical treatments.It has considerable research potential and prospect.This article reviews the current application status and research progress of apatinib in HCC,aiming to provide valuable reference basis for clinical application.

关 键 词：阿帕替尼 肝细胞癌 研究进展 

分 类 号：R735.7[医药卫生—肿瘤]